MRC1 and cancer: These results show that neoantigen quality, not merely quantity, dictates anti-tumour immunity, explain inconsistent immunotherapy responses in MMR-deficient cancers, and advocate incorporating amino acid substitution patterns into predictive biomarkers and therapy design.